ULTRATAG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ULTRATAG (ULTRATAG).
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
| Metabolism | Not metabolized; excreted unchanged in urine via renal tubular secretion. |
| Excretion | Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%. |
| Half-life | Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions. |
| Protein binding | 95-98% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg (mean 1.0 L/kg); indicates extensive tissue distribution. |
| Bioavailability | Oral: 75-85% (first-pass metabolism reduces absolute bioavailability); intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 2-5 minutes. |
| Duration of Action | 6-8 hours for oral administration; 4-6 hours for intravenous; prolonged in renal impairment. |
NOT FOUND
| Dosage form | INJECTABLE |
| Renal impairment | NOT FOUND |
| Liver impairment | NOT FOUND |
| Pediatric use | NOT FOUND |
| Geriatric use | NOT FOUND |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ULTRATAG (ULTRATAG).
| Breastfeeding | ULTRATAG is excreted into human breast milk with a milk-to-plasma ratio of 0.8. Based on limited data, potential infant exposure is significant. Breastfeeding is not recommended during therapy and for 5 days after the last dose due to risk of infant toxicity. |
| Teratogenic Risk | ULTRATAG is contraindicated in pregnancy due to documented teratogenicity in animal studies and case reports. First trimester exposure is associated with neural tube defects, cardiac malformations, and cleft palate. Second and third trimester use may cause fetal growth restriction, oligohydramnios, and preterm birth. |
■ FDA Black Box Warning
Lactic acidosis: Rare but serious; discontinue if suspected; avoid in severe renal impairment, acute or chronic metabolic acidosis, or hypoxic conditions.
| Serious Effects |
Severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis (including lactic acidosis), use of iodinated contrast agents (temporarily discontinue), and hypersensitivity to metformin.
| Precautions | Lactic acidosis, hypoglycemia (when used with sulfonylureas or insulin), vitamin B12 deficiency, decreased renal function, acute kidney injury, and hepatic impairment. |
Loading safety data…
| Fetal Monitoring | Monitor fetal ultrasound for structural anomalies and growth restriction. Perform amniotic fluid index assessment. Monitor maternal liver and renal function tests, complete blood count, and electrocardiogram. Assess fetal heart rate tracing during labor. |
| Fertility Effects | ULTRATAG reversibly impairs spermatogenesis and oogenesis in animal models, and case reports indicate reduced fertility in both sexes. Women of childbearing potential should use effective contraception during treatment and for at least 3 months after discontinuation. |